Navigation Links
Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
Date:5/5/2011

EAST HANOVER, N.J., May 5, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4). This marks the first approval of a treatment for this patient population in the US in nearly 30 years(5).

The approval was based on Phase III data from the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) trial, showing treatment with Afinitor more than doubled the time without tumor growth (median 4.6 to 11.0 months) and reduced the risk of cancer progression by 65% when compared with placebo in patients with advanced pancreatic NET (hazard ratio=0.35 [95% confidence interval (CI), 0.27 to 0.45]; p<0.001). A consistent improvement in progression-free survival was seen with Afinitor in all patient subgroups(1). The FDA determined that the safety and effectiveness of Afinitor in the treatment of patients with carcinoid tumors have not been established(4).

"The FDA approval of Afinitor represents an important step forward for patients with advanced pancreatic NET," said James Yao, MD, Associate Professor of Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. "Patients will now have access to a treatment that has been shown to significantly delay tumor growth and reduce the risk of disease progression."

Approximately 60% of pancreatic NET patients are diagnosed with advanced disease(2). This means that the cancer has already spread to other parts of the body, and is considered aggressive and difficult to treat(3). The five-year survival rate for these patients is 27%(6).

"With this approval, physicians can now offer their patients with progressive pancreatic NET a new treatment helping to fulfill a critical unmet need," said Herve Hoppenot, President
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
2. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
3. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
4. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
5. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
6. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
7. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
8. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Novartis to Expand Global Research Headquarters in Cambridge, MA
11. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... OTEMR, Inc. , ONETOUCH EMR, 2.0 has achieved ONC ... the software is capable of supporting eligible providers with ... measures required to qualify for funding under the American ... certified on July 14, 2014 by ICSA Labs ... (ONC-ACB) and is compliant in accordance with applicable criteria ...
(Date:9/17/2014)... , Sept. 17, 2014  Members of ... and Interventional Associates announced today that the ... to enhance its image sharing capabilities and provide ... any network failures. In addition, the Dicom Systems ... navigate disparate PACS systems to more effectively deliver ...
(Date:9/17/2014)... , Sept. 17, 2014 Women everywhere ... infections are not only uncomfortable, they,re often also embarrassing ... plans. pH-D Feminine Health Support ( http://ph-defense.com ) is ... It is an all-natural, homeopathic product. ... common symptoms of vaginal infection. In many cases, the ...
Breaking Medicine Technology:OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 2OTEMR, Inc.'s ONETOUCH EMR Achieves ONC HIT 2014 Edition COMPLETE EHR Certification from ICSA Labs 3Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 2Dicom Systems' Innovative Software Provides Enhanced Imaging Sharing Capabilities, as Well as Connection Reliability in the Case of Network Failure 3New Product from Vireo Systems: pH-D Feminine Health Support 2
(Date:9/17/2014)... The Food and Drug Administration (FDA) has ... consider: , 1. The appropriate indicated ... 2. The potential for adverse cardiovascular outcomes associated ... ongoing, an informally-organized litigation group subcommittee prepared a presentation ... therapy. Among others, ZKB attorney Michelle L. Kranz and ...
(Date:9/17/2014)... September 17, 2014 StartX , ... 12 companies raising rounds of funding at its Summer ... hundred investors and media, was the first such gathering ... next to the university. The presentations were delivered on ... to StartX-QB3 Labs, a 2,000 square foot life science ...
(Date:9/17/2014)... 2014 Cadiz Laser Spa offers ... procedures to clients throughout Central Texas. The newest ... Collagen Induction Therapy. Using the revolutionary Rejuvapen micro-needling ... help clients correct a wide variety of skin ... and Cadiz Laser Spa is currently offering a ...
(Date:9/17/2014)... News) -- Present-day Europeans are the descendants of ... to a new study. Previous research ... early European farmers. But, a new genetic analysis ... the descendants of Ancient North Eurasians. Nearly all ... ancestral group, researchers from Harvard Medical School said. ...
(Date:9/17/2014)... Steven Reinberg HealthDay Reporter ... uncovered a key factor to explain why antibiotic-resistant bacteria can ... DNA called plasmids appear to be the culprit. They can ... and some carry a gene that makes bacteria drug-resistant, a ... carry an antibiotic-resistant gene to a class of antibiotic called ...
Breaking Medicine News(10 mins):Health News:FDA Advisory Committee Holds Hearing on Testosterone Safety 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Revolutionary Collagen Induction Therapy is Now Available at Cadiz Laser Spa 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 2Health News:Europeans Are Descendants of at Least 3 Ancient Human Groups: Study 3Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 2Health News:Researchers Discover How Bacteria Resist Antibiotics in Hospitals 3
... new study has revealed that women diagnosed with breast ... exercise , then they should continue exercising, for ... ,Ohio State University researchers analysed 500 women, who had ... and more specifically the intensity and amount of physical ...
... smoking, by finding that regular smokers may have a higher ... never smoke. ,The study also found that while smokers ... in short run, this risk declines to the level of ... other words, both completely smoke-free life style and successful smoking ...
... is the biggest environmental issue no one's talking about," regrets ... founder of the Work Less Party, a Vancouver-based initiative aimed ... "As a society, we're working exponentially hard to decrease sustainability ... antidepressants are on the rise," he says. ,Americans ...
... it doesnt have to be that way always. ... that they have successfully managed to reduce wrinkles ... vitamin A. ,Not only did the cream ... people revealed it boosted levels of important skin repair ...
... an otherwise bleak healthcare scenario has emerged a heartening ... IM injection manufactured by the US based Institute for ... its Model List for Essential Medicines. ,Paromomycin ... (VL), the worlds second most deadly parasitic disease after ...
... prefer not to talk about, yet sufferers will go to ... overactive bladder (OAB) and it's characterized by a sudden ... ,Now, to reduce the symptoms of OAB, an Emory ... ankle to better help control the bladder. ,"Known ...
Cached Medicine News:Health News:Exercise may Help Breast Cancer Patients to Lead a Healthy Life 2Health News:Regular Smokers are at the Risk of Developing Depression 2Health News:Work Less to Sustain Planet Earth, Say Activists 2Health News:Work Less to Sustain Planet Earth, Say Activists 3Health News:Wrinkles can Be Really Ironed Out, Thanks to Vitamin A 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 2Health News:A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List 3Health News:Stimulating the Ankle Can Help Patients With Overactive Bladder 2
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: